Providing Flexibility in Oncology Early Clinical Development

This white paper considers the recent paradigm shifts in oncology drug development and explores the current requirements of early-phase oncology trials. By remaining attuned to the dynamic nature of oncology drug development, time, cost and risk can all be efficiently minimized while evaluating and successfully managing safety and ethical considerations during the early clinical development journey.